Osteoclast differentiation and function are crucial for maintaining bone homeostasis and preserving skeletal integrity. N6-methyladenosine (m 6 A) is an abundant mRNA modification that has recently been shown to be important in regulating cell lineage differentiation. Nevertheless, the effect of m 6 A on osteoclast differentiation remains unknown. In the present study, we observed that the m 6 A level and methyltransferase METTL3 expression increased during osteoclast differentiation. Mettl3 knockdown resulted in an increased size but a decreased bone-resorbing ability of osteoclasts. The expression of osteoclast-specific genes (Nfatc1, c-Fos, Ctsk, Acp5 and Dcstamp) was inhibited by Mettl3 depletion, while the expression of the cellular fusion-specific gene Atp6v0d2 was upregulated. Mechanistically, Mettl3 knockdown elevated the mRNA stability of Atp6v0d2 and the same result was obtained when the m 6 A-binding protein YTHDF2 was silenced. Moreover, the phosphorylation levels of key molecules in the MAPK, NF-κB and PI3K-AKT signaling pathways were reduced upon Mettl3 deficiency. Depletion of Mettl3 maintained the retention of Traf6 mRNA in the nucleus and reduced the protein levels of TRAF6. Taken together, our data suggest that METTL3 regulates osteoclast differentiation and function through different mechanisms involving Atp6v0d2 mRNA degradation mediated by YTHDF2 and Traf6 mRNA nuclear export. These findings elucidate the molecular basis of RNA epigenetic regulation in osteoclast development.
Introduction
N6-methyladenosine (m 6 A) is produced by a methylation modification at the N6 position of adenosine residues in RNA. As the most prevalent modification of eukaryotic mRNA, it has garnered considerable research interest in recent years [1, 2] . In mammals, m 6 A is installed by a methyltransferase complex comprising methyltransferase-like 3 (METTL3), methyltransferase-like 14 (METTL14) and Wilms' tumor 1-associated protein (WTAP). METTL3 is the first identified component of the m 6 A methyltransferase complex and acts as the catalytic core, while WTAP and METTL14 function as regulatory and substrate recognition subunits, respectively [3, 4] . In contrast, the m 6 A modification is removed by two demethylases, fat mass and obesity-associated protein (FTO) and α-ketoglutarate-dependent dioxygenase homolog 5 (ALKBH5) [5, 6] . The m 6 A modification functions by recruiting YT521-B homology (YTH) domain family proteins, such as YTHDF1-3 and YTHDC1 and 2 [7] . As a dynamic epigenetic modification, m 6 A has been shown to participate in multiple aspects of mRNA metabolism, including alternative splicing, stability, nuclear export
Results

m 6 A Content and Expression of m 6 A Modification-Related Genes during Osteoclastogenesis
To determine whether m 6 A participates in the regulation of osteoclastogenesis, we established an osteoclastogenesis model using RANKL-induced RAW264.7 cells and M-CSF/RANKL-induced bone marrow-derived macrophages (BMMs). As determined by TRAP staining, RAW264.7 cells and BMMs were able to generate mature osteoclasts ( Figure S1A ,B). The mRNA and protein levels of the osteoclast markers Ctsk and Acp5 significantly increased ( Figure S1C-F) , further confirming the osteoclast differentiation of RAW264.7 cells and BMMs.
Next, m 6 A methylation levels and m 6 A modification-related gene expression were detected in osteoclast precursor cells and osteoclasts. As shown in Figure 1A , the total m 6 A content increased after RAW264.7 cells differentiated into osteoclasts. The mRNA and protein levels of the m 6 A methylase METTL3 were upregulated after osteoclast differentiation. However, neither the mRNA nor the protein levels of m 6 A demethylases (FTO and ALKBH5) were altered ( Figure 1B,C) . These results obtained in RAW264.7 cells were further validated in primary BMMs. A higher total m 6 A content and an increased METTL3 expression was observed after BMMs differentiated into osteoclasts, while the expression of FTO and ALKBH5 were not altered ( Figure 1D -F). These data suggested a possible role of METTL3 in regulating osteoclastogenesis. 6 A modification-related enzymes were assessed by Western blotting. Gapdh was used as an internal control. The results represent the mean ± SD (n = 3). ** P < 0.01; *** P < 0.001.
Mettl3 Knockdown Has No Effect on the Proliferation of Osteoclast Precursor Cells
To investigate whether METTL3 affects osteoclast precursor cell proliferation, specific short hairpin RNAs (shRNAs) were transfected into cells to knock down Mettl3. METTL3 protein and mRNA expression was remarkably inhibited after interference with Mettl3-shRNA, especially in the Mettl3-sh2 group, which was utilized in the subsequent experiments (Figure 2A,B) . As shown in Figure 2C , the total m 6 A content in RAW264.7 cells and BMMs significantly decreased upon Mettl3 knockdown. A CCK8 assay was performed to measure cell growth of RAW264.7 cells and BMMs. The results showed that no significant differences were observed between cells transfected with Mettl3-shRNA and Mettl3-shCtrl at any time point of the experiment ( Figure 2D ,E), indicating that METTL3 had no effect on the proliferation of osteoclast precursor cells. 6 A content in RAW264.7 cells and BMMs was measured by quantifying m 6 A RNA methylation. Cell growth of RAW264.7 cells (D) and BMMs (E) in Mettl3-shRNA and Mettl3-shCtrl groups was detected using a CCK8 assay after culturing for different times. The results are presented as the mean ± SD (n = 3). Significant differences relative to the Mettl3-shCtrl group. * P < 0.05; ** P < 0.01; *** P < 0.001.
Mettl3 Knockdown Regulates Osteoclastic Differentiation and Bone Resorption
Mettl3-deficient RAW264.7 cells were cultured in the presence of RANKL and Mettl3-deficient BMMs were treated with RANKL and M-CSF. To elucidate the role of METTL3 in the osteoclast differentiation process, TRAP staining was performed in Mettl3-deficient cells after osteoclastogenesis. As shown in Figure 3A -D, fewer mature osteoclasts were observed in the Mettl3-shRNA group, while osteoclasts differentiated from Mettl3-deficient cells were larger and had more nuclei than those from the control groups. To evaluate whether METTL3 affects the bone resorption ability of osteoclasts, a pit formation assay was then performed. We observed that the osteoclasts differentiated from Mettl3-difficient cells exhibited lower bone resorption activity than those from the control group ( Figure 3E,F) . Consistent with the decreased number and bone-resorbing activity of mature osteoclasts, Mettl3 knockdown downregulated the mRNA and protein levels of the osteoclast differentiation-related genes Nfatc1, c-Fos and Dcstamp, as well as bone resorption-related genes, including Ctsk and Acp5. However, the mRNA and protein expression of Atp6v0d2, a fusion-associated gene, was upregulated after Mettl3 knockdown ( Figure 3G,H,I ). These different changes in gene expression suggest that diverse regulatory mechanisms of METTL3 are involved in osteoclast differentiation.
Mettl3 and Ythdf2 Knockdown Increase Atp6v0d2 mRNA Stability during Osteoclast Differentiation
Atp6v0d2, the sole upregulated gene in the Mettl3-knockdown cells, participates in the fusion of osteoclast precursor cells and regulates the size of osteoclasts [33] . Based on the negative correlation between the levels of Atp6v0d2 and Mettl3, we hypothesized that the augmentation of Atp6v0d2 mRNA expression following Mettl3 knockdown was due to its enhanced mRNA stability. To test this possibility, an RNA decay assay was performed to assess Atp6v0d2 mRNA stability. As shown in Figure 4A , mRNA stability profiling revealed that Atp6v0d2 mRNA tended to have a longer half-life in the Mettl3-shRNA group than in the Mettl3-shCtrl group.
YTHDF2 is an m 6 A-binding protein that recognizes and destabilizes m 6 A-modified mRNA [34] . To further investigate whether YTHDF2 is involved in the regulation of Atp6v0d2 mRNA stability, we used specific siRNAs to knock down Ythdf2. As shown in Figure 4B ,C, compared with the control group, the Ythdf2-siRNA#1 group exhibited a higher knockdown efficiency at both the mRNA and protein levels. Consistent with the Mettl3 knockdown results, Ythdf2 deficiency promoted the expression of Atp6v0d2 mRNA ( Figure 4D ). The results of RNA stability assays showed that Ythdf2 deficiency enhanced Atp6v0d2 mRNA stability and prolonged its half-life period ( Figure 4E) . Overall, the data demonstrated that loss of METTL3 increased the mRNA stability of Atp6v0d2 via YTHDF2 participation.
Mettl3 Knockdown Inactivates the RANKL-Induced MAPK, NF-κB and PI3K-AKT Signaling Pathways
During osteoclast differentiation and activation, RANKL-induced signaling pathways, including the MAPK, NF-κB and PI3K-AKT signaling pathways, trigger the expression of transcription factors and downstream osteoclast-specific genes. To investigate whether the downregulation of osteoclast genes in Mettl3-knockdown cells is due to the inhibition of signaling pathways, we assessed the phosphorylation levels of ERK, P38, JNK, IKKα/β, P65, IκBα and AKT by Western blotting. The results showed that knockdown of Mettl3 markedly decreased the p-ERK, p-P38 and p-JNK levels ( Figure 5A ). In addition, the levels of phosphorylated IKKα/β, P65, IκBα and AKT were also reduced in Mettl3-knockdown cells ( Figure 5B ,C). These results indicated that Mettl3 knockdown inhibited the activation of the MAPK, NF-κB and AKT signaling pathways in RANKL-induced osteoclastogenesis. The average size of each osteoclast (×10 3 µm 2 ) was determined by image analysis using the ImageJ software. (E,F) Resorption activity of osteoclasts in the Mettl3-shCtrl and Mettl3-shRNA groups was assessed by pit formation assay. The "black" scale bars represent 100 µm. The osteoclast resorption area as a percentage of total area was calculated using Image-Pro. (G,H) The mRNA levels of Nfatc1, c-fos, Ctsk, Acp5, Dcstamp and Atp6v0d2 were measured by qRT-PCR. (I) The protein levels of NFATC1, c-FOS, CTSK, TRAP, DCSTAMP and ATP6V0D2 were assessed by Western blotting. The band densities were analyzed using ImageJ. β-Actin was used as a normalization control. All of the data are presented as the mean ± SD (n = 3). Significant differences relative to the Mettl3-shCtrl group. * P < 0.05; ** P < 0.01; *** P < 0.001. The mRNA expression level of Atp6v0d2 in the siCtrl and siYthdf2 groups was assessed by qRT-PCR at 0, 3 and 6 h after actinomycin D-mediated transcriptional inhibition. β-Actin was used as a normalization control. The data are presented as the mean ± SD (n = 3). ** P < 0.01; *** P < 0.001. All of the data are presented as the mean ± SD (n = 3). ** P < 0.01; *** P < 0.001.
Mettl3 Knockdown Promotes the Retention of Traf6 Transcripts in the Nucleus
TRAF6, a major adaptor protein, is recruited by the RANKL-RANK interaction and subsequently mediates the initiation of MAPK, NF-κB and PI3K-AKT signaling to promote osteoclast differentiation and activation [24] . To further understand the mechanisms by which Mettl3 knockdown inhibits the RANKL-induced signaling pathways, we focused on the upstream component TRAF6. The TRAF6 protein levels decreased in the Mettl3-shRNA group compared to those in the Mettl3-shCtrl group within 60 min of RANKL stimulation ( Figure 6A,B) . However, the total Traf6 mRNA was not differentially expressed after Mettl3 knockdown ( Figure 6C ). Because m 6 A modifications can affect the nuclear export and intracellular distribution of mRNAs [8] , we subsequently assessed nucleocytoplasmic fractionations of Traf6 mRNA via qRT-PCR. As shown in Figure 6D , Mettl3 knockdown decreased the levels of Traf6 mRNA in the cytoplasm but increased its presence in the nucleus, especially upon RANKL stimulation. These data indicated the role of METTL3 in regulating Traf6 mRNA intracellular distribution during osteoclast differentiation, which may further affect TRAF6 protein levels and the activation of downstream signaling pathways. (D) The distribution of Traf6 mRNA in the nucleus and cytoplasm was analyzed by qRT-PCR. The data are presented relative to the levels of β-actin (cytoplasm) or U6 (nucleus). Significant differences relative to the Mettl3-shCtrl group. All of the data are presented as the mean ± SD (n = 3). ** P < 0.01; *** P < 0.001.
Discussion
m 6 A has been identified as a prevalent mRNA modification in nearly all eukaryotes since being discovered in the 1970s [35, 36] . The use of high-throughput sequencing techniques following m 6 A RNA immunoprecipitation is a major breakthrough in the study of the distribution and function of m 6 A [37, 38] . The orchestration of the m 6 A methyltransferase complex and demethylases forms reversible m 6 A methylation modifications affecting nascent pre-mRNA processing [39] . Previous research has revealed the role of m 6 A modification in various physiological and pathological phenomena, such as stem cell self-renewal and differentiation, tumorigenesis and immunoregulation [40] [41] [42] . Osteoclast development is essential for preserving skeletal integrity. Abnormal osteoclast differentiation and activation can trigger the disturbance of bone homeostasis and leads to multiple bone-resorbing diseases [25] . In recent years, mounting evidence has suggested that epigenetic regulation, including DNA methylation and histone modification, are involved in osteoclastogenesis [43] [44] [45] . Nevertheless, as a primary RNA epigenetic regulator, the role of m 6 A in osteoclastogenesis has rarely been considered. To explore whether m 6 A methylation participates in regulating osteoclast differentiation, we used both RAW264.7 cells and murine bone marrow-derived macrophages as osteoclast precursors to induce osteoclast formation. Subsequently, we assessed the expression levels of the methylase METTL3 and the demethylases FTO and ALKBH5, as well as the total m 6 A content. The data showed that METTL3 but not FTO or ALKBH5 expression increased after osteoclast differentiation and the total m 6 A levels were also upregulated upon osteoclast induction. These results suggested that METTL3-dependent m 6 A methylation might play a role in osteoclastogenesis.
In mammals, METTL3 acts as the catalytic subunit of the m 6 A methyltransferase complex and is responsible for installing the m 6 A modification on mRNA. Perturbations in m 6 A levels due to the depletion or overexpression of Mettl3 can lead to physiological disorders. Deletion of Mettl3 from the hematopoietic system inhibits hematopoietic stem cell (HSC) differentiation and increases HSC accumulation in the bone marrow [46] . Overexpression of METTL3 in porcine adipocytes attenuates lipid accumulation by downregulating the expression of the adipogenesis-related genes PPARγ and FAS [47] . To investigate the role of METTL3 in osteoclastogenesis, we silenced Mettl3 and assessed the effect on osteoclast precursor proliferation. A previous study reported that securing an adequate number of osteoclast precursor cells is an essential prerequisite for osteoclast formation [48] . In our study, the results indicated that Metttl3 knockdown did not affect the proliferation of RAW264.7 cells or BMMs. Subsequently, we assessed whether Mettl3 knockdown affected osteoclast differentiation and bone-resorbing activity. TRAP staining results showed that Mettl3 knockdown reduced the number of mature osteoclasts with larger size and more nuclei. The expression levels of transcription factors involved in osteoclast differentiation, such as c-Fos and Nfatc1, also decreased in Mettl3-deficient cells. Osteoclasts derived from Mettl3-deficient cells presented lower lytic activity when measured by the pit formation assay. The expression of Acp5 and Ctsk, which play essential roles in bone-resorbing activity, was downregulated when Mettl3 was silenced. The data indicated that the bone resorption activity of osteoclasts was attenuated after Mettl3 knockdown, along with the inhibited osteoclast differentiation. Intriguingly, unlike the downregulated genes above, the Atp6v0d2 expression level increased due to Mettl3 deficiency. Atp6v0d2 is a fusion-associated gene that accelerates cell-cell fusion and the multinucleation process during osteoclastogenesis [33] . The increased expression of this cell fusion molecule offers a possible explanation for the giant multinucleated osteoclast phenotype that was observed in TRAP-positive cells. Our result was in accordance with several previous studies that the change of osteoclast size and nuclei number sometimes is inconsistent with that of osteoclast number in the process of osteoclastogenesis [49] [50] [51] [52] . The different expression pattern of the genes might suggest that diverse mechanisms are involved in the METTL3-mediated regulation of osteoclast differentiation.
The data from our study showed that Atp6v0d2 was the only gene whose expression level was negatively related to the m 6 A methyltransferase METTL3. m 6 A modification exerts its biological functions through selective recognition by specific binding proteins, among which YTHDF2 is responsible for the degradation of m 6 A-containing mRNA [7, 9] . The C-terminal domain of YTHDF2 can selectively bind to m 6 A-containing RNAs while the P/Q/N-rich N-terminus brings the YTHDF2-mRNA complex to cytoplasmic foci (P bodies) and recruits CCR4-NOT deadenylase complex to the RNA [34] . Based on this knowledge, we hypothesized that Mettl3 deficiency might lead to inhibited mRNA degradation mediated by YTHDF2, thus promoting the stability of the Atp6v0d2 mRNA. To test this hypothesis, we first demonstrated that Mettl3 knockdown led to the promotion of Atp6v0d2 mRNA stability. Next, we knocked down Ythdf2 and measured the mRNA level and stability of Atp6v0d2. Our results proved that, consistent with Mettl3 deficiency, Ythdf2 knockdown elevated the expression and stability of Atp6v0d2 mRNA. These findings demonstrated that the loss of METTL3 inhibited Atp6v0d2 mRNA degradation mediated by YTHDF2. Previous study showed that ATP6V0D2 is identified as a key component of autophagosome-lysosome fusion machinery in macrophages, which is required for the macrophage-specific completion of autophagy [53] . Autophagy is a cellular self-protection mechanism and plays an important role in osteoclast differentiation and function [54] [55] [56] . However, whether Atp6v0d2 takes effect in the modulation of osteoclast autophagy remains unclear. The role of Atp6v0d2 in regulation of autophagy in Mettl3-deficient osteoclasts needs further study.
During osteoclastogenesis, the activation of RANKL-induced MAPK, NF-κB and PI3K-AKT signaling pathways can trigger the expression of downstream transcription factors to promote mature osteoclast formation and function [20] . Mature, multinucleated osteoclasts are capable of bone resorption and express genes that typify the osteoclast lineage [27] . Studies have revealed that m 6 A modifications play crucial roles in regulating the abovementioned signaling pathways during the inflammatory response and cancer progression [57, 58] . METTL3 knockdown inhibits the activation of LPS-induced NF-κB and MAPK signaling pathways in human dental pulp cells [57] . In addition, a reduction in m 6 A modifications following METTL3 depletion represses the PI3K-AKT signaling pathway and attenuates the proliferation and migration of human gastric cancer cells [58] . In our study, Mettl3 knockdown downregulated the expression of osteoclast-specific genes, including Nfatc1, c-Fos, Acp5, Ctsk and Dcstamp. To elucidate whether the downregulation of genes in Mettl3-knockdown cells was due to the suppression of RANKL-induced signaling pathways, we assessed the phosphorylation levels of key signal molecules in the MAPK, NF-κB and PI3K-AKT pathways. The data demonstrated that Mettl3 knockdown decreased the phosphorylated levels of ERK, P38, JNK, IKKα/β, P65, IκBα and AKT, suggesting that the RANKL-induced MAPKs, NF-κB and PI3K-AKT pathways were inhibited.
The initiation of the above RANKL-induced signaling pathways is mediated by TRAFs, which are recruited by the interaction of RANKL and RANK during osteoclastogenesis [59] . Among TRAF family members, TRAF6 is the most important and indispensable factor for osteoclast development, as a Traf6 knockout generates a severe osteopetrosis phenotype in mice due to the inability of osteoclast precursors to form functional osteoclasts [60] . TRAF6 binding to the trimerized cytoplasmic tail of RANK triggers the activation of the MAPK, NF-κB and PI3K-AKT pathways to promote differentiation of osteoclast precursors into osteoclasts [61] . Previously published m 6 A-IP-seq datasets have shown that Traf6 mRNA contains m 6 A sites and is a target gene of METTL3 in RAW264.7 cells [62] . To evaluate whether Mettl3 knockdown affects TRAF6 expression during osteoclastogenesis, we examined the protein level of TRAF6 and the data showed that TRAF6 protein levels were markedly downregulated in Mettl3 knockdown cells. m 6 A methylation has been confirmed to affect the nuclear export of mRNA. The m 6 A reader YTHDC1 mediates nuclear to cytoplasmic transport of methylated mRNAs by interacting directly with SRSF3 and the export receptor NXF1 [8] . METTL3 depletion in intestinal porcine epithelial cells blocks the LPS-induced inflammation response by entrapping TRAF6 mRNA in the nucleus [63] . To investigate whether METTL3 affects Traf6 mRNA nuclear export in osteoclasts, the intracellular distribution of Traf6 mRNA was assessed via qRT-PCR. The data showed that the loss of Mettl3 entrapped Traf6 mRNA in the nucleus, especially after RANKL stimulation. Further evidence, such as Fluorescence In Situ Hybridization (FISH) using RNA probes specific to Traf6 transcripts, would be more convincing. Based on these findings, we concluded that the Mettl3 knockdown-mediated entrapment of the Traf6 transcript in the nucleus may suppress the activation of the MAPK, NF-κB and PI3K-AKT signaling pathways, which would consequently attenuate the expression of osteoclast-specific genes and inhibit osteoclastic differentiation and bone resorption.
Taken together, the results of this study indicated that the levels of m 6 A and METTL3 are increased during osteoclastogenesis. Mettl3 knockdown inhibited osteoclast differentiation and bone-resorbing activity via regulating osteoclast-related mRNA metabolism. Mechanistically, Mettl3 depletion promoted the stability and the expression of Atp6v0d2 mRNA via YTHDF2 involvement. The retention of Traf6 transcripts in the nucleus inhibited the activation of the MAPK, NF-kB and PI3K-AKT signaling pathways after Mettl3 knockdown, which may play a key role in suppressing osteoclast-specific gene expression and osteoclast function (Figure 7 ). These findings provide insights into the role of METTL3-dependent m 6 A modification in osteoclastogenesis, which may contribute to the identification of novel therapeutic targets for bone resorption diseases. The influence of METTL3-dependent m 6 A methylation on skeletal health and bone homeostasis needs to further explore in vivo. 6 A modification in osteoclast differentiation. Mettl3 knockdown causes the retention of Traf6 mRNA in the nucleus, which might result in the inactivation of RANKL-induced signaling pathways and suppress osteoclast-specific gene expression, as well as inhibit osteoclast formation and function. In addition, Mettl3 knockdown upregulates Atp6v0d2 mRNA expression and stability via YTHDF2 involvement, leading to the formation of large, multinucleated osteoclasts.
Materials and Methods
Cell Culture and Osteoclast Differentiation
RAW264.7 cell lines were obtained from the American Type Culture Collection (ATCC; Manassas, VA, USA). Cells were cultured in alpha-minimum essential medium (α-MEM; Gibco, New York, NY, USA) supplemented with 10% fetal bovine serum (FBS; Gibco, Carlsbad, CA, USA) at 37 • C under an atmosphere with 5% CO 2 . Mouse bone marrow cells were isolated from the long bones of 6-to 8-week-old C57BL/6 mice (Animal Center of Sun Yat-sen University) by flushing the bone marrow cavity with α-MEM. Then, the cells were cultured in a-MEM containing 10% FBS overnight to separate the suspended cells. The suspended cells were then collected and cultured in α-MEM containing 10% FBS with 30 ng/mL M-CSF (Sino Biological, Beijing, China) for 3 days to obtain BMMs, which were used as osteoclast precursor cells.
For osteoclast differentiation, RAW264.7 cells were stimulated with 50 ng/mL RANKL (R&D Systems, Minneapolis, MN, USA) for 5 days, while BMMs were treated with 30 ng/mL M-CSF and 50 ng/mL RANKL for 5 days. The culture medium was changed every two days. Cells treated without RANKL served as a negative control. Mature osteoclasts were detected by TRAP staining.
TRAP Staining
After being induced to differentiate into osteoclasts, the cells were fixed with 4% formaldehyde for 20 min at room temperature and then stained for TRAP (Sigma, St. Louis, MO, USA) according to the manufacturer's instructions. TRAP-positive cells with 3 or more nuclei were counted as osteoclasts [20] .
Pit Formation Assay
A pit formation assay was performed to evaluate the bone-resorptive function of osteoclasts. RAW264.7 cells or BMMs were seeded into 24-well Corning Osteo assay plates (Corning Incorporated Life Science, Corning, NY, USA) and cultured in the appropriate medium for 7 days to promote osteoclastogenesis. After culturing, the plates were washed with sodium hypochlorite and PBS. The resorption pits were observed under a phase-contrast microscope (Axiovert 40; Zeiss, Jena, Germany) and the osteoclast resorption area was calculated as a percentage of the total area using Image-Pro (Media Cybernetics, Silver Spring, MD, USA).
Cell Proliferation Assay
A CCK8 (Cell Counting Kit-8; Dojindo Laboratories, Kumamoto, Japan) assay was used to measure cell proliferation. RAW264.7 cells or BMMs were seeded into 96-well plates at a density of 2 × 10 4 cells/mL. RAW264.7 cells were cultured in α-MEM containing 10% FBS, while BMMs were cultured in α-MEM containing 10% FBS and 30 ng/mL M-CSF. At 24, 48, 72, 96 and 120 h of incubation, 10 µL of CCK8 was added to every well. Then, the optical density (OD value) was recorded at 450 nm using a microplate reader (Sunrise, Tecan, Switzerland).
Total m6A Measurement
Total RNA was isolated from RAW264.7 cells or BMMs and the total m 6 A content was detected in 200 ng RNA aliquots using an EpiQuik m 6 A RNA Methylation Quantification kit (Colorimetric) (EpiGentek, Farmingdale, NY, USA) according to the manufacturer's instructions. Table 1 ) and a nonspecific shRNA were designed and cloned into a GV248 vector (GENECHEM, Shanghai, China). A recombinant lentiviral vector was transfected into HEK293T cells (ATCC, Manassas, VA, USA) and the packaged lentiviruses were collected after 48 h and transduced into RAW264.7 cells and BMMs. Transfected cells were then maintained in complete medium supplemented with 6 µg/mL puromycin (Sigma, St. Louis, MO, USA) for 3 days. The stable clones were cultured in medium supplemented with 3 µg/mL puromycin and the knockdown of Mettl3 was confirmed by both a Western blotting assay and qRT-PCR. Ythdf2 in RAW264.7 cells was knocked down using a siRNA strategy. Briefly, cells were seeded overnight in 6-well plates at a density of 4 × 10 5 cells/mL before transfection with 50 nM small interfering RNA (siYthdf2 or the nontarget siRNA control) (Invitrogen, Carlsbad, CA, USA) and Lipofectamine TM 3000 (Invitrogen, Carlsbad, CA, USA) according to the manufacturer's instructions. The siRNA sequences are listed in Table 2 . Total RNA from cells was extracted using RNAzol (MRC, Cincinnati, OH, USA) and purified. Concentrations of RNA were determined spectrophotometrically. cDNA was prepared from one microgram of total RNA using a PrimeScript TM RT Reagent kit (TaKaRa, Kyoto, Japan). Subsequently, qRT-PCR was performed using a Light Cycler 96 instrument (Roche, Basel, Switzerland). The relative expression of the tested genes was normalized to that of the housekeeping genes Actb, Gapdh or U6. The primer sequences for this experiment are listed in Table 3 . Table 3 . Sequences for qRT-PCR.
Forward Primer (5 -3 )
Reverse Primer (5 -3 )
RNA Stability Assay and mRNA Half-Life Calculation
The cells were stimulated with 50 ng/mL RANKL for 60 h and then treated with actinomycin D (5 µg/mL) (Sigma, St. Louis, MO, USA) to stall mRNA transcription. Cells were collected at the indicated time points to assess mRNA degradation and the relative mRNA levels of the tested genes were analyzed by qRT-PCR. The relative levels of mRNA at 3 and 6 h after transcription inhibition were analyzed to measure the stability. The half-life of mRNA was calculated according to the mRNA concentration and the mRNA degradation rate.
Cytoplasmic and Nuclear RNA Fractionation
Cytoplasmic and nuclear RNA were isolated and purified using a Cytoplasmic and Nuclear RNA Purification kit (Norgen Biotek Corp, Thorold, ON, Canada) following the manufacturer's instructions. The purified cytoplasmic and nuclear RNA were used for downstream qRT-PCR analysis.
Western Blotting
The cells were lysed for 30 min on ice using RIPA lysis buffer (Beyotime, Haimen, China) containing protease inhibitor cocktail and phosphatase inhibitor cocktail (Cwbiotech, Beijing, China). Protein concentrations were measured using a bicinchoninic acid (BCA) protein assay kit (Beyotime, Haimen, China). Protein samples were separated by 8% sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) and then transferred onto polyvinylidene fluoride (PVDF) membranes (Millipore, Billerica, MA, USA). The membranes were then blocked in TBST containing 5% BSA for 1 h at room temperature. Next, the membranes were incubated with primary antibodies against METTL3, YTHDF2 and ALKBH5 (1:1000; Proteintech, Chicago, IL, USA); FTO, CTSK, TRAP, TRAF6 and GAPDH Technology, Boston, MA, USA) for 1 h after washing with TBST. An enhanced chemiluminescence system (Millipore, Billerica, MA, USA) was used to visualize specific protein bands. The band densities were quantified and normalized to those of β-ACTIN and GAPDH using ImageJ v1.47 (National Institutes of Health, Bethesda, MD, USA).
Statistical Analysis
All experiments were conducted in triplicate and repeated three times. All data were presented as the mean ± standard deviation (SD) and SPSS v20.0 (SPSS Inc., Chicago, IL, USA) was used to analyze the data. Comparisons of two groups were performed using the two-tailed unpaired t-test. P < 0.05 was reported as significant. Funding: This research received no external funding.
